Interpace Biosciences®, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements (Tables)

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2021

Schedule of Financial Instrument Measured on Recurring Basis

The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below:

	As of March 31, 2021				Fair Value Measurements
	Carrying		Fair		As of March 31, 2021
	Amount		Value		Level 1		Level 2		Level 3
					(unaudited)
Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	2,175	$	2,175	$	-	$	-	$	2,175
Other long-term liabilities:
Warrant liability ⁽²⁾		62		62		-		-		62
	$	2,237	$	2,237	$	-	$	-	$	2,237

	13

	As of December 31, 2020				Fair Value Measurements
	Carrying		Fair		As of December 31, 2020
	Amount		Value		Level 1		Level 2		Level 3

Liabilities:
Contingent consideration:
Asuragen ⁽¹⁾	$	2,216	$	2,216	$	-	$	-	$	2,216
Other long-term liabilities:
Warrant liability ⁽²⁾		21		21		-		-		21
	$	2,237	$	2,237	$	-	$	-	$	2,237

⁽¹⁾⁽²⁾See Note 9, Accrued Expenses and Long-Term Liabilities

Schedule of Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation

Certain of the Company’s non-financial assets, such as other intangible assets and goodwill, are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

								Cancellation		Adjustment
								of Obligation/		to Fair Value/
	December 31, 2020		Payments			Accretion		Conversions Exercises		Mark to Market			March 31, 2021
	(unaudited)
Asuragen	$	2,216	$	(119	)	$	135	$	-	$	(57	)	$	2,175

Underwriters Warrants		21		-			-		-		41			62
	$	2,237	$	(119	)	$	135	$	-	$	(16	)	$	2,237